BLACK WEEKSLahvičky −15 % · kity −10 % · ostatní −5 %s kódemDoprava po Německu zdarma od 200 €

Tato stránka byla přeložena automaticky a může obsahovat chyby. Jste rodilý mluvčí? Rádi uvítáme vaši zpětnou vazbu a opravy.Poslat zpětnou vazbu

The Peptide Desk The Peptide Desk
KPV Oral, fotografie produktu
Immune Oral

KPV Oral

Immune Oral

  • Odesíláme z Německa

Objednávka

Cena za kus - Doprava po Německu zdarma od 200 € během Black Weeks
  • DHL se sledováním zásilky
  • Diskrétní balení

4.6 z 5 na Trustpilotu73 hodnocení

V kostce

KPV Oral v číslech

Klíčové údaje z našeho lexikonu.

Celé heslo v lexikonu
Class
Anti-inflammatory tripeptideoral
Use
Oraltablet, 500mcg
Sizes
250 to 500 mcg2 sizes in the shop

Znalosti

Vše o KPV Oral

Podrobné informace připravujeme.

Dávkování

Načítání informací o dávkování …

Více v lexikonu

FAQ

Časté dotazy

Zdroje ke každé odpovědi: heslo v lexikonu

Máte ještě dotaz?

Napište nám, náš tým vám pomůže.

Are there studies on KPV as a tablet?

No. There is no published study on the tablet. The gut studies in mice also gave KPV by mouth, though: in drinking water or in carriers that release the compound only in the colon.

Is KPV approved or studied in humans?

No. There is no approval and as of 26 October 2026 ClinicalTrials.gov lists not a single trial with KPV. All data come from cell experiments and animal models.

Why via the gut in particular?

The transporter PepT1 carries small peptides of two or three building blocks into cells, KPV included. PepT1 is barely present in the healthy colon but increased in chronic bowel inflammation. So KPV preferentially reaches the inflamed areas. In mice without PepT1 the effect of KPV on colon tumours after inflammation was absent.

What do the gut models show?

With KPV in the drinking water the inflammation marker MPO fell by about 50 and 30 percent of the rise (two colitis models) and weight loss was smaller. In a model of colon cancer after inflammation fewer tumours formed, but not in a genetic tumour model without inflammation.

What do carriers like nanoparticles add?

They protect KPV on its way through stomach and small intestine and release it in the colon. In nanoparticles a 12,000-fold lower concentration gave a similar effect. A newer conjugate brought 3.8 times more KPV into the colon and worked better even at a 20-fold smaller amount.

Which side effects are known?

There are no solid data because KPV has never been tested in a registered human trial. The nanoparticle carriers did not damage gut cells in cell experiments. That cannot be transferred to humans.